【FINTEC 0150 交流专区】（前名 ASIABIO）

misery

讲了那么久。。。到现在只见到量有少少增了些，股价却不动。。。。难道要学PJI那样？

kingsimon

回复  misery


    是咯??我老板一直叫我进 最后我买了100 粒 。 0.65 他说会起炒到 两毛多 ？？
elvis 发表于 6-12-2010 04:15 PM

   
这两天都大热！你和你老板有加码吗

icy97

亞洲生物能源230萬售廠

大馬財經  2011-10-11 10:47
（吉隆坡11日訊）亞洲生物能源（ASIABIO，0150，創業板貿服組）以230萬令吉脫售巴生1棟工廠，以套現和注入孵化基金（Incubation Fund），供未來發展用途。

該公司發文告表示，脫售計劃料為截至2012年1月31日止財政年淨利帶來15萬3千186令吉盈利，或每股4仙盈利。（星洲互動）

icy97

亚洲生化营收增80%

财经新闻 财经  2011-12-07 11:57
（吉隆坡6日讯）亚洲生化（AsiaBio，0150，创业板）截至2011年10月31日财年第三季，营业额按年增长80%，报149万7000令吉，上财年同期为83万2000令吉。

不过，该公司在第三季则蒙受91万6000令吉净亏损，比上财年同期的16万3000令吉净亏损严重；每股亏损从上财年的0.06仙，扩大至0.25仙。

首9个月营业额下滑6.8%报511万9000令吉，上财年同期为549万8000令吉；相较于上财年同期的69万6000令吉净利，首9个月录得134万9000令吉；上财年同期的0.27仙每股盈利，也在今财年转为每股亏损0.37仙。

亚洲生化表示，由于集团参与高科技领域，初期的资金投入免不了。有鉴于此，预期集团表现将受到各种波动。[NanYang]

elvis

财经新闻 财经  2011-12-07 11:57
（吉隆坡6日讯）亚洲生化（AsiaBio，0150，创业板）截至2011年10月31日 ...
icy97 发表于 8-12-2011 01:39 AM

    可靠吗这一个股。。手上还有500LOT，，老板手上1500LOT。。该留还是丢？？

696969sm

AsiaBio，0150，创业板 要来了，创业板的股都起到七七八八了，下一只就是他了。

icy97

SUMMARY OF KEY FINANCIAL INFORMATION

31/01/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/01/2012	31/01/2011	31/01/2012	31/01/2011
		$$'000	$$'000	$$'000	$$'000
1	Revenue	398	771	5,517	6,258
2	Profit/(loss) before tax	-11,365	-14	-11,050	1,167
3	Profit/(loss) for the period	-11,400	-62	-11,142	1,124
4	Profit/(loss) attributable to ordinary equity holders of the parent	-11,301	-428	-12,650	268
5	Basic earnings/(loss) per share (Subunit)	-3.09	-0.17	-3.46	0.10
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0835		0.1195

icy97

亞洲生物能源550萬‧全購Hexa81%

大馬  2012-04-11 14:49
（吉隆坡10日訊）亞洲生物能源（ASIABIO,0150,創業板貿服組）以550萬令吉，全面收購生物能源設備供應商Hexa的81%股權，以把握更多交叉銷售的機會。

這項收購將以內部資金進行，預見該收購提振未來盈利。該公司早在去年9月，以190萬令吉收購Heza的19%股權。（星洲日報）

icy97

亞洲生化 末季虧損擴大

企業財經24/05/2012 21:43
（吉隆坡24日訊）亞洲生化（ASIABIO，0150，創業板貿易股）截至今年1月31日末季淨虧損，經過調整后擴大58%至1995萬令吉。

該公司向馬證交所報備指出，原本末季呈報的淨虧損為1265萬令吉，如今在納入投資撥備損失后，淨虧損擴大730萬令吉至1995萬令吉。

報備文件指出，由于希臘退出歐元區的風險加劇，恐將衝擊生化柴油（Biodiesel）業，公司在公佈第4季業績后，外委審計師建議為生化柴油業的投資作撥備損失。

“董事局在與外委審計師商討后，決定接受他們的意見作進一步的撥備損失，業績才會出現差額。”[ChinaPress]

icy97

SUMMARY OF KEY FINANCIAL INFORMATION

30/04/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/04/2012	30/04/2011	30/04/2012	30/04/2011
		$$'000	$$'000	$$'000	$$'000
1	Revenue	303	1,394	303	1,394
2	Profit/(loss) before tax	9	515	9	515
3	Profit/(loss) for the period	9	515	9	515
4	Profit/(loss) attributable to ordinary equity holders of the parent	12	-131	12	-131
5	Basic earnings/(loss) per share (Subunit)	0.00	-0.04	0.00	-0.04
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0645		0.0644

icy97

购Hexa Bonanza股权 亚洲生化冀8月杪完成
财经新闻 财经  2012-07-27 21:00
（吉隆坡27日讯）亚洲生化（AsiaBio，0150，创业板）冀望，今年8月杪完成Hexa Bonanza私人有限公司剩余81%股权的收购案。

亚洲生化执行董事梁国强（译音）表示，若亚洲生化在8月杪完成收购献议，将有助于公司在截至2013年1月杪的财年扭转亏蚀。

“我们对下半年的业务发展有信心，我们也相信公司将获利。”

他是在今日的公司常年股东大会后，发表上述言论。

截至目前，亚洲生化一共持有Hexa Bonanza的19%股权，而Hexa Bonanza的董事周岩那和刘耀辉（人名皆译音）则各别持股31%和50%。

梁国强指出：“Hexa Bonanza的业务主要是供应生物粒化（bio-pelletising）机器。我们预测，生物科技领域下半年的表现将比上半年来得好。

伺机投资生物能源
“我们正放眼潜在机会来投资生物科技和生物能源领域，不过，现阶段仍不适宜过早发布任何文告。”

他披露，归咎于生物柴油业务进一步减值，致使亚洲生化截至2012年1月杪财年，税后亏损和少数股东权益共计1995万令吉。

根据大马交易所的资料显示，亚洲生化截至今年4月30日的财年首季已转亏为盈，税前盈利录得9000令吉。不过，该盈利水平仍低于上财年同季的51万5000令吉。[Nanyang]

kkk_0

量从28号放大。0。08可以偷鸡下吧？

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/07/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/07/2012	31/07/2011	31/07/2012	31/07/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	790	2,228	1,093	3,622
2	Profit/(loss) before tax	-1,802	486	-1,793	1,001
3	Profit/(loss) for the period	-1,802	451	-1,793	966
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,787	-302	-1,775	-433
5	Basic earnings/(loss) per share (Subunit)	-0.47	-0.09	-0.46	-0.12
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	6.0000		6.4400

icy97

亚洲生化私配3820万股

财经新闻 财经  2012-12-01 11:57
（吉隆坡30日讯）亚洲生化（AsiaBio，0150，创业板）建议私下配售最高3820万股新普通股，每股面值10仙，相等于10%缴足股本。

截至今日，公司缴足股本为3820万令吉，包括3亿8200万股。

亚洲生化有意透过西金（KAF）把上述新股配售给第三方投资者。

公司也预计，假设私下配售新股的参阅价为每股10仙，私下配售活动将可筹措382万令吉。[Nanyang]

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”) • PROPOSED PRIVATE PLACEMENT
On behalf of the Board of Directors of AsiaBio, KAF Investment Bank Berhad wishes to announce that the Company is proposing to undertake the Proposed Private Placement (as defined in the attached complete announcement).

Attachments ASIABIO - Announcement.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/10/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/10/2012	31/10/2011	31/10/2012	31/10/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	274	1,497	1,367	5,119
2	Profit/(loss) before tax	-434	-686	-2,227	315
3	Profit/(loss) for the period	-449	-708	-2,242	258
4	Profit/(loss) attributable to ordinary equity holders of the parent	-458	-916	-2,233	1,349
5	Basic earnings/(loss) per share (Subunit)	-0.12	-0.25	-0.58	0.37
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0588		0.0644

icy97

亚洲生化卖Platinum Nanochem 1.56% 换英国Biofutures 1.08%

财经新闻 财经  2012-12-12 11:48
（吉隆坡11日讯）亚洲生化（AsiaBio，0150，创业板）建议脱售旗下Platinum Nanochem私人有限公司的1.56%股权，换取英国上市公司Biofutures国际、价值99万9107英镑（约484万1673令吉）的1.08%股权。

亚洲生化今天发文告宣布，与多名卖家透过换股方式，脱售Platinum Nanochem私人有限公司，予伦敦另类投资市场（AIM）上市的Biofutures国际。

Biofutures国际将以价值8080万8081英镑（约3亿9150万令吉）的新股，支付有关卖家，包括持有Platinum Nanochem私人公司1.56%股权的亚洲生化。

因此，亚洲生化完成脱售后，将持有Biofutures国际的1.08%股权。英国上市的Biofutures国际，主要业务为投资或收购能源或水电公司。

亚洲生化指出，上述脱售行动是要促进Platinum Nanochem私人公司倒置收购Biofutures国际，以在伦敦另类投资市场上市，并获得更多资金协助扩展业务。

“完成后，脱售行动估计可为我们带来465万令吉净收入，或增加每股净资产约1.22仙。”

截至2011年12月31日，Platinum Nanochem私人公司写下高达3202万5492令吉的净亏损。同时，Biofutures国际则创下1393万8000英镑净亏损。

亚洲生化预期未来4个月内完成脱售行动。另外，亚洲生化今天早上9时8分宣告暂停交易，直至早上10时8分恢复交易。

闭市时，亚洲生化并没有太大波动，以7仙平盘挂收，成交量有52万9800股。[Nanyang]

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ABT” OR “THE COMPANY”) - PROPOSED DISPOSAL OF 1,143,434 ORDINARY SHARES OF RM1.00 EACH, REPRESENTING 1.56% OF THE TOTAL ORDINARY SHARES, IN PLATINUM NANOCHEM SDN BHD (FORMERLY KNOWN AS PLATINUM ENERGY SDN BHD) TO BIOFUTURES INTERNATIONAL PLC (“BIP”) FOR A TOTAL CONSIDERATION OF ￡999,107 (EQUIVALENT TO RM4,841,673) (“PROPOSAL”)
The Board of Directors of ABT wishes to announce the execution of a Share Sale Agreement (“SSA”) on 10 December 2012 between Biofutures International Plc. (“BIP”) and the various vendors of Platinum Nanochem Sdn Bhd (formerly known as Platinum Energy Sdn Bhd) (“PNSB”), including ABT (hereinafter referred to as the “Vendors”), for the sale by the Vendors and the purchase by BIP of the entire issued share capital of PNSB comprising of 73,481,290 ordinary shares of RM1.00 each, 4,000,000 redeemable convertible cumulative preference shares of RM0.10 each (“RCCPS”) and 15,000,000 redeemable convertible cumulative preference shares of RM1.00 each (“RCCPS B”) (hereinafter referred to as “Sale Shares”), for a total consideration of ￡80,808,081 (“Purchase Price”) to be satisfied by the issuance of 1,154,401,154 fully paid, new ordinary shares in the share capital of BIP (“Consideration Shares”). This announcement is dated 11 December 2012.

Attachments ABT - Disposal Platinum (11 12 2012).pdf

icy97

icy97 发表于 29-11-2012 12:09 AM
亚洲生化私配3820万股

财经新闻 财经  2012-12-01 11:57

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”) •        PROPOSED PRIVATE PLACEMENT OF UP TO 38,200,000 NEW ORDINARY SHARES OF RM0.10 EACH IN ASIABIO REPRESENTING UP TO TEN PERCENT (10%) OF THE ISSUED AND PAID-UP SHARE CAPITAL OF ASIABIO (“PROPOSED PRIVATE PLACEMENT”)
We refer to the announcement dated 28 November 2012 in relation to the Proposed Private Placement. On behalf of the Board of Directors of AsiaBio, KAF Investment Bank Berhad wishes to announce further information of the Proposed Private Placement. This announcement is dated 18 December 2012.

Attachments ASIABIO - Reply to Bursa Query.pdf

icy97

亞洲生物能源600萬售eCompazz IT 28%

大馬  2013-01-18 17:39
（吉隆坡18日訊）亞洲生物能源（ASIABIO，0150，創業板貿服組）以600萬令吉，脫售eCompazz IT公司的28%股權。

該公司發文告指出，由於eCompazz IT公司前景充滿挑戰，而且不再是業務焦點，因此決定展開脫售行動。

另外，亞洲生物能源也與Nexfuel及Hexa Bonanza公司聯營合作發展生物質混合物粒化業務，其中亞洲生物能源初步階段將祭出290萬令吉資金，並持有該聯營計劃的50.1%股權。（星洲日報／財經）

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ABT” OR “THE COMPANY”) PROPOSED DISPOSAL OF 28% EQUITY STAKE IN ECOMPAZZ IT SDN BHD COMPRISING 84,000 ORDINARY SHARES OF RM1.00 EACH TO THE PURCHASERS, LIM HAI TENG AND LIM CHEOW CHUEN, FOR A CASH CONSIDERATION AMOUNT OF RM6,000,000
The Board of Directors of ABT wishes to announce that the Company, as the Vendor, has on 17 January 2013 entered into a Share Sale Agreement with Lim Hai Teng and Lim Cheow Chuen as the Purchasers, for the disposal of a 28% equity stake in eCompazz IT Sdn Bhd comprising 84,000 ordinary shares of RM1.00 each for a cash consideration sum of RM6,000,000. This announcement is dated 17 January 2013.

Attachments AsiaBio-Proposed Disposal.pdf

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ABT” OR “THE COMPANY”) PROPOSED JOINT VENTURE BETWEEN ABT, NEXFUEL SDN BHD (“NEXFUEL”) AND HEXA BONANZA SDN BHD (“HEXA”) ON THE DEVELOPMENT OF HEXA’S BIOMASS COMPOST PELLETIZING BUSINESS USING OIL PALM TRUNK PEELED LUMBER MACHINE AND TECHNOLOGY SUPPLIED BY NEXFUEL
The Board of Directors of ABT wishes to announce the execution of a Joint Venture Agreement (“JVA”) on 17 January 2013 between ABT, Nexfuel as the technology provider and Hexa as the special purpose vehicle on the joint venture to develop Hexa’s biomass compost pelletizing business using Nexfuel’s oil palm trunk peeled lumber machine and technology and to carry out the research and development of technologies relating to such (hereinafter referred to as the “JV Project”).   The JV Project is a “green” initiative since it aims to convert biomass from oil palm logs after its felling for replanting exercise into peeled lumber, which when combined with veneer can be used to produce block board panels for the building materials industry. This announcement is dated 17 January 2013.

Attachments AsiaBio-Proposed Joint Venture.pdf

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ABT” OR “THE COMPANY”) - PROPOSED DISPOSAL OF 28% EQUITY STAKE IN ECOMPAZZ IT SDN BHD COMPRISING 84,000 ORDINARY SHARES OF RM1.00 EACH TO THE PURCHASERS, LIM HAI TENG AND LIM CHEOW CHUEN, FOR A CASH CONSIDERATION AMOUNT OF RM6,000,000 (“PROPOSED DISPOSAL”)
We refer to Section 2.3 of the Company’s announcement dated 17 January 2013 on the Proposed Disposal. We wish to clarify that the Purchase Price was arrived at on negotiated, willing-buyer willing-seller basis based on the audited net assets of eCompazz group of companies as at 31 January 2012 of approximately RM2.3 mil and taking into consideration of the audited profit after tax of RM3.2 mil for the financial year ended 31 January 2012, as well as the prospects of eCompazz in the future.  The Purchase Price arrived at represents a PE multiple of about 6.7 times the audited profits of eCompazz for the latest financial year ended 31 January 2012. This announcement is dated 22 January 2013.